Pfizer COVID-19 vaccine appointments are available to our patients. Sign up for Connect today to schedule your vaccination. Continue your routine care with us by scheduling an in-person appointment or Video Visit.

Clinical pharmacology of mivacurium chloride (BW B1090U) infusion: comparison with vecuronium and atracurium.

TitleClinical pharmacology of mivacurium chloride (BW B1090U) infusion: comparison with vecuronium and atracurium.
Publication TypeJournal Article
Year of Publication1988
AuthorsAli HH, Savarese JJ, Embree PB, Basta SJ, Stout RG, Bottros LH, Weakly JN
JournalBr J Anaesth
Date Published1988 Nov
KeywordsAdolescent, Adult, Atracurium, Humans, Infusions, Intravenous, Isoquinolines, Neuromuscular Nondepolarizing Agents, Pseudocholinesterase, Time Factors, Vecuronium Bromide

Mivacurium chloride (BW B1090U) is a new, short-acting non-depolarizing neuromuscular blocking agent. It is a synthetic bis-benzylisoquinolinium diester, which is hydrolysed rapidly by plasma cholinesterase. This study compares mivacurium, atracurium and vecuronium by continuous i.v. infusion. The duration of mivacurium infusion ranged from 29.5 to 286 min. The steady state infusion rates necessary to maintain 95 (SEM 4)% twitch suppression were: mivacurium 8.3 (0.7) micrograms kg-1 min-1; atracurium 7.9 (0.4) micrograms kg-1 min-1; vecuronium 1.2 (0.3) micrograms kg-1 min-1. Following infusions of mivacurium, various recovery times (for example: 25-75%, 6.9 (0.3) min; 25-95%, 11.0 (0.4) min; 5-95% 14.5 (0.4) min) did not differ significantly from those following single bolus doses. Recovery times following cessation of mivacarium infusions were approximately 50% of those for equivalent durations of infusion of atracurium (10.9 (0.3) min for 25-75% recovery and 26.6 (0.4) min for 5-95% recovery). For vecuronium, corresponding recovery times were 13.8 (0.9) and 32.0 (1.2) min, respectively. Comparative recovery times for mivacurium were 40-50% of those for vecuronium. There was a significant correlation between the infusion rate of mivacurium required to maintain 95% twitch depression and the plasma cholinesterase activity of individual subjects.

Alternate JournalBr J Anaesth
PubMed ID2905143